Potential Differences in Kidney Allograft Outcomes Between Ethnicities When Converting to Sirolimus Base Immunosuppression

Transplantation Proceedings

Volumn 41, Issue 10, 2009, Pages 4131-4137

  Patel, N ^a   Taber, D J ^a   Weimert, N A ^a   Fleming, J N ^a   Egidi, F M ^a   McGillicuddy, J ^b   Bratton, C F ^b   Lin, A ^b   Chavin, K D ^b   Baliga, P K ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AFRICAN AMERICAN; ARTICLE; DEMOGRAPHY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNICITY; EUROPEAN AMERICAN; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RACE DIFFERENCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CONTINENTAL POPULATION GROUPS; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 71249115335     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.09.088     Document Type: Article

References (17)

1. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357 (2007) 2562
2. Mulay A.V., Cockfield S., Stryker R., et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systemic review of evidence. Transplantation 82 (2006) 1153
3. Ojo A.O., Hanson J.A., Wolfe R.A., et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 57 (2000) S1208
4. Sarnak M.J., Levey A.S., Shoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology and Epidemiology and Prevention. Circulation 108 (2003) 2154
5. Joosten S., van Kooten C., and Leendert C.P. Pathogenesis of chronic allograft rejection. Transpl Int 16 (2003) 137
6. deMattos A., and Olyaei A. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 35 (2000) 333
7. Sehgal S.N. Sirolimus: its discovery, biological properties. Transplant Proc 35 suppl 3A (2003) 7S
8. Podder H., Podbielski J., Hussein I., et al. Sirolimus improved the two-year outcome of renal allografts in African-American patients. Transplant Int 4 (2001) 135
9. Hricik D.E., Anton H.A., Knauss T.C., et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation 74 (2002) 189
10. Flechner S.M., Kobashigawa J., and Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 22 (2008) 1
11. Levey A., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137
12. McLaren A.J., Jassem W., Gray R.W.D., et al. Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clin Transplant 13 (1999) 266
13. Lo A., Egidi A.F., Gaber L.W., et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cardaveric renal transplantation. Transplantation 77 (2004) 1228
14. Egidi M.F., Cowan P.A., Naseer A., et al. Conversion to sirolimus in solid organ transplantation: a single-center experience. Transplant Proc 35 suppl 3A (2003) 131S
15. Franco A.F.V., Martini D., Abensur H., et al. Proteinuria in transplant patients associated with sirolimus. Transplant Proc 39 (2007) 449
16. Shishido S., Asanuma H., Nakai H., et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 4 (2003) 1046
17. Buchler M., Caillard S., Barbier S., et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 7 (2007) 2522